Workflow
Heart recovery
icon
Search documents
New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump
Prnewswireยท 2025-08-31 16:15
Core Insights - The recent clinical data presented at the European Society of Cardiology Congress indicates that the routine use of Impella CP in patients with heart attack and cardiogenic shock leads to a significant absolute mortality reduction of 16.3% over a period of up to 10 years compared to standard care [1][4] - Patients using Impella CP gained an average of 600 additional days alive when compared to the control group at the 10-year mark [1][4] - The survival benefit of Impella CP has been confirmed to increase year-over-year, validating the findings from the original DanGer Shock randomized controlled trial [2][3] Company and Product Insights - Impella CP is recognized as the first mechanical circulatory support device proven in a randomized controlled trial to provide both short-term and long-term survival benefits for patients experiencing cardiogenic shock due to ST-elevation myocardial infarction (STEMI) [4] - The American College of Cardiology and American Heart Association have upgraded Impella to a class 2a guideline based on the original trial data presented in May 2024 [4] - Approximately 750,000 individuals in the United States experience STEMI annually, with an incidence rate of cardiogenic shock in these patients reaching up to 10% [5] Technology and Market Position - Impella is described as the world's smallest heart pump, designed to temporarily take over the heart's pumping function, allowing the heart to rest and recover while ensuring the flow of oxygenated blood throughout the body [6] - Johnson & Johnson MedTech is committed to addressing significant health challenges through its cardiovascular portfolio, which includes advanced technologies for heart recovery and circulatory restoration [7] - The company positions itself as a leader in treating heart rhythm disorders and is focused on innovations that can profoundly impact global health, particularly in heart failure and stroke [8]